Automate Your Wheel Strategy on CAH
With Tiblio's Option Bot, you can configure your own wheel strategy including CAH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAH
- Rev/Share 926.1917
- Book/Share -7.9083
- PB -13.0681
- Debt/Equity -2.6048
- CurrentRatio 0.9436
- ROIC 0.1279
- MktCap 38312432040.0
- FreeCF/Share 10.1625
- PFCF 15.7083
- PE 24.7271
- Debt/Assets 0.154
- DivYield 0.0126
- ROE -0.5014
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CAH | Wells Fargo | Equal Weight | Overweight | -- | $179 | June 3, 2025 |
| Upgrade | CAH | Jefferies | Hold | Buy | $140 | $150 | Feb. 5, 2025 |
| Upgrade | CAH | TD Cowen | Hold | Buy | $130 | $144 | Jan. 8, 2025 |
| Upgrade | CAH | Evercore ISI | In-line | Outperform | -- | $140 | Jan. 7, 2025 |
| Upgrade | CAH | BofA Securities | Neutral | Buy | $132 | $145 | Jan. 6, 2025 |
| Upgrade | CAH | Wells Fargo | Underweight | Equal Weight | $101 | $127 | Dec. 13, 2024 |
| Resumed | CAH | Mizuho | -- | Outperform | -- | $139 | Dec. 4, 2024 |
News
Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth
Published: June 11, 2025 by: Benzinga
Sentiment: Positive
BofA Securities analyst Allen Lutz reiterated the Buy rating on Cardinal Health, Inc. CAH, raising the price forecast from $165 to $170.
Read More
Cramer's Stop Trading: Cardinal Health
Published: June 10, 2025 by: CNBC Television
Sentiment: Neutral
Jim Cramer breaks down why he's keeping an eye on shares of Cardinal Health.
Read More
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
Read More
Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt
Published: May 26, 2025 by: MarketBeat
Sentiment: Neutral
Lately, the market has been delivering more plot twists to investors than a season of Severance. Solid tech earnings come in tandem with pulled guidance from public-facing companies like airlines and retailers.
Read More
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
Published: May 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Read More
Cardinal (CAH) Upgraded to Buy: Here's Why
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Should Value Investors Buy Cardinal Health (CAH) Stock?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
63 Top Dividend Growth Stocks For May 2025
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low (
Read More
Cardinal Health releases new report on the cell and gene therapy industry
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry.
Read More
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Cardinal Health, Inc. (CAH) Q3 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Cardinal Health, Inc. (NYSE:CAH ) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Allen Lutz - Bank of America Joanna Dynak - Evercore Eric Percher - Nephron Michael Cherny - Leerink Partners Kevin Caliendo - UBS George Hill - Deutsche Bank Eric Coldwell - Baird Erin Wright - Morgan Stanley Daniel Grosslight - Citi Charles Rhyee - TD Cowen Steve Baxter - Wells Fargo Brian Tanquilut - Jefferies Steven …
Read More
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Read More
Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Cardinal Health (CAH) Beats Q3 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardinal Health (CAH) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.08 per share a year ago.
Read More
Cardinal Health lifts full-year profit forecast again on specialty medicine sales
Published: May 01, 2025 by: Reuters
Sentiment: Positive
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs.
Read More
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP 1 operating earnings were $730 million; GAAP diluted EPS was $2.10 Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35 Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00 GI Alliance announces expansion into urology specialty therapeutic area DUBLIN, Ohio , May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter …
Read More
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Read More
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Read More
Here's Why Cardinal Health (CAH) is a Strong Value Stock
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Cardinal Health (CAH) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Read More
Should Value Investors Buy Cardinal Health (CAH) Stock?
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Forget Tech: Buy These 5 Non-Tech High Flyers of Q1
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Here we discuss five non-tech stocks that have provided double-digit returns year to date, defying the negative trends of U.S. stock markets. These are TPR, WEC, CNP, CME and CEH.
Read More
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Cardinal Health (CAH) closed at $133.98 in the latest trading session, marking a +0.93% move from the prior day.
Read More
About Cardinal Health, Inc. (CAH)
- IPO Date 1983-08-04
- Website https://www.cardinalhealth.com
- Industry Medical - Distribution
- CEO Mr. Jason M. Hollar
- Employees 47922